Your browser is no longer supported. Please, upgrade your browser.
Finch Therapeutics Group, Inc.
Index- P/E- EPS (ttm)- Insider Own49.25% Shs Outstand47.38M Perf Week-4.05%
Market Cap653.47M Forward P/E- EPS next Y-2.27 Insider Trans0.00% Shs Float24.09M Perf Month-2.58%
Income- PEG- EPS next Q-0.42 Inst Own11.60% Short Float1.01% Perf Quarter-5.07%
Sales9.48M P/S68.93 EPS this Y-89.60% Inst Trans-19.04% Short Ratio3.69 Perf Half Y-11.37%
Book/sh4.82 P/B2.90 EPS next Y-18.80% ROA- Target Price- Perf Year-
Cash/sh3.59 P/C3.89 EPS next 5Y- ROE- 52W Range11.56 - 22.50 Perf YTD-34.52%
Dividend- P/FCF- EPS past 5Y- ROI42.00% 52W High-37.96% Beta-
Dividend %- Quick Ratio18.60 Sales past 5Y- Gross Margin- 52W Low20.76% ATR1.10
Employees131 Current Ratio18.60 Sales Q/Q98.30% Oper. Margin- RSI (14)47.78 Volatility6.06% 8.30%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.23 Prev Close14.19
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume66.16K Price13.96
Recom1.30 SMA20-3.28% SMA50-1.06% SMA200-3.88% Volume15,376 Change-1.62%
Apr-13-21Initiated Jefferies Buy $29
Apr-13-21Initiated Evercore ISI Outperform $34
Apr-13-21Initiated BofA Securities Buy $25
Sep-08-21 07:00AM  
Sep-07-21 07:00AM  
Aug-18-21 08:54AM  
Aug-10-21 03:54PM  
Jun-28-21 07:00AM  
May-28-21 07:00AM  
May-13-21 07:00AM  
May-06-21 07:00AM  
Apr-27-21 07:00AM  
Mar-19-21 04:25PM  
Mar-18-21 10:32PM  
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FERRANTE DOMENIC JDirectorMar 23Buy17.00102,9411,749,997636,195Mar 25 06:04 PM
SMISEK JEFFERY ADirectorMar 23Buy17.0088,2351,499,9951,694,541Mar 25 06:08 PM